TY - JOUR
T1 - Acute lipotoxicity regulates severity of biliary acute pancreatitis without affecting its initiation
AU - Durgampudi, Chandra
AU - Noel, Pawan
AU - Patel, Krutika
AU - Cline, Rachel
AU - Trivedi, Ram N.
AU - Delany, James P.
AU - Yadav, Dhiraj
AU - Papachristou, Georgios I.
AU - Lee, Kenneth
AU - Acharya, Chathur
AU - Jaligama, Deepthi
AU - Navina, Sarah
AU - Murad, Faris
AU - Singh, Vijay P.
N1 - Funding Information:
Supported by grant RO1DK092460 (V.P.S.), the Clinical Translational Science Institute supported by the National Institutes of Health through grants UL1RR024153 and UL1TR000005 (V.P.S., S.N.), by a startup package from the Department of Medicine, University of Pittsburgh (V.P.S.). This project used the Luminex Core Laboratory, University of Pittsburgh Cancer Institute Cancer Biomarkers Facility, which is supported in part by NIH grant P30CA047904.
PY - 2014/6
Y1 - 2014/6
N2 - Obese patients have worse outcomes during acute pancreatitis (AP). Previous animal models of AP have found worse outcomes in obese rodents who may have a baseline proinflammatory state. Our aim was to study the role of acute lipolytic generation of fatty acids on local severity and systemic complications of AP. Human postpancreatitis necrotic collections were analyzed for unsaturated fatty acids (UFAs) and saturated fatty acids. A model of biliary AP was designed to replicate the human variables by intraductal injection of the triglyceride glyceryl trilinoleate alone or with the chemically distinct lipase inhibitors orlistat or cetilistat. Parameters of AP etiology and outcomes of local and systemic severity were measured. Patients with postpancreatitis necrotic collections were obese, and 13 of 15 had biliary AP. Postpancreatitis necrotic collections were enriched in UFAs. Intraductal glyceryl trilinoleate with or without the lipase inhibitors resulted in oil red O-positive areas, resembling intrapancreatic fat. Both lipase inhibitors reduced the glyceryl trilinoleate-induced increase in serum lipase, UFAs, pancreatic necrosis, serum inflammatory markers, systemic injury, and mortality but not serum alanine aminotransferase, bilirubin, or amylase. We conclude that UFAs are enriched in human necrotic collections and acute UFA generation via lipolysis worsens pancreatic necrosis, systemic inflammation, and injury associated with severe AP. Inhibition of lipolysis reduces UFA generation and improves these outcomes of AP without interfering with its induction.
AB - Obese patients have worse outcomes during acute pancreatitis (AP). Previous animal models of AP have found worse outcomes in obese rodents who may have a baseline proinflammatory state. Our aim was to study the role of acute lipolytic generation of fatty acids on local severity and systemic complications of AP. Human postpancreatitis necrotic collections were analyzed for unsaturated fatty acids (UFAs) and saturated fatty acids. A model of biliary AP was designed to replicate the human variables by intraductal injection of the triglyceride glyceryl trilinoleate alone or with the chemically distinct lipase inhibitors orlistat or cetilistat. Parameters of AP etiology and outcomes of local and systemic severity were measured. Patients with postpancreatitis necrotic collections were obese, and 13 of 15 had biliary AP. Postpancreatitis necrotic collections were enriched in UFAs. Intraductal glyceryl trilinoleate with or without the lipase inhibitors resulted in oil red O-positive areas, resembling intrapancreatic fat. Both lipase inhibitors reduced the glyceryl trilinoleate-induced increase in serum lipase, UFAs, pancreatic necrosis, serum inflammatory markers, systemic injury, and mortality but not serum alanine aminotransferase, bilirubin, or amylase. We conclude that UFAs are enriched in human necrotic collections and acute UFA generation via lipolysis worsens pancreatic necrosis, systemic inflammation, and injury associated with severe AP. Inhibition of lipolysis reduces UFA generation and improves these outcomes of AP without interfering with its induction.
UR - http://www.scopus.com/inward/record.url?scp=84901008740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901008740&partnerID=8YFLogxK
U2 - 10.1016/j.ajpath.2014.02.015
DO - 10.1016/j.ajpath.2014.02.015
M3 - Article
C2 - 24854864
AN - SCOPUS:84901008740
SN - 0002-9440
VL - 184
SP - 1773
EP - 1784
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 6
ER -